Monoclonal Antibodies
JNJ-67856633 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial tests JNJ-67856633, an oral drug, in patients with certain blood cancers that have returned or resisted treatment. The drug works by blocking a protein that helps cancer cells grow. The study aims to find the safest dose and see if the drug is effective.
Anti-metabolites
Triple Drug Therapy for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing a new combination of drugs to treat leukemia. The drugs are ibrutinib, fludarabine, and pembrolizumab. The trial is open to patients with leukemia who have not responded to other treatments.
Popular Filters
Trials for CLL Patients
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
Trials for Mantle Cell Lymphoma Patients
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
Trials for CD19 Positive Patients
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Trials for CD20 Positive Patients
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called Mosunetuzumab, both alone and with another drug called atezolizumab, in patients with blood cancers that have not responded to other treatments. These drugs work by helping the immune system find and destroy cancer cells. Atezolizumab is a medication that has been approved for use in various cancers, including breast cancer, and has shown effectiveness when combined with other treatments.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
BTK Inhibitor
Acalabrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new medication, acalabrutinib, to see if it is safe and effective in treating people with chronic lymphocytic leukemia. The trial will last for approximately 72 months and will enroll 600 participants.
B-cell lymphoma-2 (BCL-2) inhibitor
Venetoclax + Ibrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
Phase 3 Trials
BCL-2 Inhibitor
Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab for Chronic B-Cell Leukemia
Recruiting2 awardsPhase 3
Louisville, Kentucky
This trial is comparing two treatments for leukemia, one with ibrutinib and venetoclax, and the other with obinutuzumab and chlorambucil. The goal is to see which of these treatments results in better progression-free survival, as assessed by an independent review committee.
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Spokane, Washington
This trial tests a new drug (nemtabrutinib) with an existing one (venetoclax) in patients with CLL or SLL who haven't responded to other treatments. The drugs work together to stop cancer growth and kill cancer cells. Venetoclax is a selective Bcl-2 inhibitor approved for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Anti-metabolites
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Anti-tumor antibiotic
Obinutuzumab + Venetoclax vs. Chlorambucil for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing a new combination of drugs for people with CLL and other medical conditions. The trial will last about a year, with follow-up for up to 9 years.
Trials With No Placebo
Monoclonal Antibodies
ONO-7018 for Non-Hodgkin's Lymphoma and Chronic B-Cell Leukemia
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing ONO-7018, a new drug designed to treat certain blood cancers that have not responded to other treatments. It works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and check the drug's safety and effectiveness.
Monoclonal Antibodies
JNJ-80948543 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial tests JNJ-80948543, a new medicine that helps the immune system fight B-cell non-Hodgkin lymphoid malignancies. It works by connecting immune cells to cancer cells, aiding in their destruction. The study aims to find the best dose and schedule while monitoring safety and effectiveness over an extended period.
LOXO-338 for Blood Cancers
Recruiting1 awardPhase 1
Miami, Florida
This trial is testing a new drug, LOXO-338, to treat advanced blood cancer in patients who haven't responded to standard treatments. If effective alone, it will also be tested with another drug, pirtobrutinib, to see if the combination works better.
MALT1 Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Monoclonal Antibodies
JNJ-75348780 for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial tests JNJ-75348780, a new medicine that helps the immune system fight blood cancers in patients whose cancers have returned or did not respond to other treatments. It works by connecting immune cells to cancer cells, helping the immune system attack the cancer.
Monoclonal Antibodies
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a new drug called JNJ-64264681 to find the best dose and ensure it is safe. It focuses on patients with specific blood cancers, namely B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The drug aims to attack and kill the cancer cells in these patients.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.